Kumar L, Bajpal V, Dua H
Indian J Cancer. 1989 Mar;26(1):14-6.
Prognosis in cases of advanced Non Hodgkin's Lymphoma refractory to primary chemotherapy - continues to be poor. In search of suitable alternative we have recently treated six such patients with continuous, intravenous infusion of vincristine for five days. All patients had a variety of histological types and had received earlier primary combination chemotherapy including Vincristine by Intravenous bolus injection. A total of 21 courses (average 3.5) were given. Three patients (50%) achieved objective-partial response. Duration of response varied from two to nine months (mean 4.5 months). Toxicity was low with minimal myelosuppression and no increased neurotoxicity occurred. Vincristine infusion treatment may provide better palliation in advanced refractory Non Hodgkin's lymphoma and suggests the possibility of its use in combination chemotherapy protocols in untreated patients.
对初始化疗难治的晚期非霍奇金淋巴瘤患者的预后仍然很差。为寻找合适的替代方案，我们最近对6例此类患者进行了持续5天的长春新碱静脉输注治疗。所有患者具有多种组织学类型，且此前均接受过包括静脉推注长春新碱在内的初始联合化疗。共进行了21个疗程（平均3.5个疗程）。3例患者（50%）达到客观部分缓解。缓解持续时间从2个月至9个月不等（平均4.5个月）。毒性较低，骨髓抑制轻微，未出现神经毒性增加。长春新碱输注治疗可能为晚期难治性非霍奇金淋巴瘤提供更好的姑息治疗，并提示其在未经治疗患者的联合化疗方案中使用的可能性。
